Table 3 The effect of herbal medicine for premenstrual syndrome
# | Intervention | Frequency | Sample | 2 cycles of pre-rating | Initial state M | Outcome | Control | Adverse | P-value |
|---|---|---|---|---|---|---|---|---|---|
(dosage/day) -form | (Tx Duration) | Size | (Improved rate or end-of-Tx score) | (no of CG) | Events | ||||
10 | Vitex Agnus castus17** (VAC, BNO 1095) 40 mg -Tablet | 1/day | 33 | Confirmed | PMSD sum score 29.38 ± 7.63 (p = 0.752) | PMSD sum score 14.66 ± 0.52 | Placebo | No notable AE observed | =0.0001 |
(3 cycles) | (34) | ||||||||
11 | Vitex Agnus castus18 (VAC, BNO 1095, 4.0 mg of dried ethanolic (70%)) 40 mg -Tablet | 2/day | 101 | Confirmed | PMSD 29.13 ± 7.88 (p = 0.4017) | PMSD 6.41 ± 7.94 | Placebo | No serious AE observed | <0.05 |
(3 cycles) | PMTS 26.17 ± 4.79 (p = 0.1649) | PMTS 9.92 ± 9.01 | (101) | ||||||
12 | Vitex Agnus castus extract19** (AC extract) | 1/day | 19 | Confirmed | DSR 171.758.1 (p > 0.05) HAM-D 15.24.7 (p > 0.05) CGI-SI 4.11.4 (p > 0.05) | DSR 82.849.5 | Fluoxetine | No serious AE observed from TG | >0.1 |
HAM-D 7.64.3 | (19) | ||||||||
20-40 mg –Tablet | (2 cycles) | CGI-I 1.20.7 five symptoms diminished 50% or more | 2CG: Sexual dysfunction | ||||||
13 | Vitex Agnus castus20 (Vitex agnus extract) | 1/day | 62 | Confirmed | DSR 30% higher score @ LP | Better than CG | Placebo | No serious AE observed | <0.0001 |
@ LP | (66) | ||||||||
40 drops (4.5 mg) -Liquid | (6 cycles) | ||||||||
14 | Hypericum Perforatum21 | 2/day | 17 | Confirmed | DSR score in LP 12.6 | DSR score 5.80 (F [1,30] = 4.82; p = 0.04; partial Z2 = 0.14) | Placebo | No serious AE observed | >0.05 |
(Li 160 (80% methanolic dry extract, 0.18% hypericin, 3.38% hyperforin) 900 mg -Tablet | (2 cycles) | (15) | |||||||
15 | Hypericum Perforatum22 (St. John’s wart extract, 300 mg of extract, 900 ug of hypericin) 1800ug hypericin (600 mg) -Tablet | 2/day | 64 | Confirmed | MD score 326.33§ | MD score 230.28 (p ≤ 0.007) | Placebo | No serious AE observed | <0.007 |
(61) | |||||||||
(2 cycles) | |||||||||
16 | Hypericum Perforatum23 | 2/day | 85 | Confirmed | DSR 149.07 | DSR 86.13 | 2 Cellulose | No serious AE observed | <0.05 |
(extract N/A) two 1340 ug hypericin -Tablet | (2 cycles) | Anxiety 41.15 ± 9.74 Crying 20.52 ± 11.73 Depression 29.26 ± 7.49 Craving 22.01 ± 11.03 Hydration 36.13 ± 8.50 | Anxiety 23.08 ± 14.78 (p = 0.223) Crying 5.87 ± 10.23 (p = 0.001, 71% reduction) Depression 13.82 ± 6.48 (p < 0.001, 52% reduction) Craving 17.26 ± 7.41 (p < 0.001) Hydration 26.10 ± 10.18 (p < 0.090) | Tablets | |||||
(85) | |||||||||
17 | Xiao Yao San or Dan Zhi Xiao Yao San8 -Powder form | 3/day | 31 | Confirmed | Diagnosed as PMS | Physical MDQ 68.9% reduction | Placebo | No AE | <0.001 |
@ LP | Physical MDQ psychological MDQ BDI ANX ANG PSS diagnosed as PMS (p < 0.005) | Psychological MDQ 74.8% reduction | (30) | ||||||
(3 cycles) | |||||||||
BDI 43.1% reduction ANX 23.8% reduction ANG 39.3% reduction PSS 16.4% reduction (p < 0.001) | |||||||||
18 | Crocus sativus (saffron) 24 30 mg -Tablet | 2/day | 24 | Confirmed | DSR < 50 PMS diagnosed by HDRS | 50% reduction in severity of symptoms by DSR and HDRS (P < 0.001) | Placebo | No severe AE reported | <0.001 |
(2 cycles) | (23) | ||||||||
19 | Elsholtzia splendens 25 120 mg -Tablet | 1/day | 10 | Not recorded | BDI 33.50 ± 5.82 | BDI 23.60 ± 4.79 (p < 0.01) STAI 48.10 ± 5.20 (p < 0.05) STAI 52.00 ± 6.18 | Placebo | None reported | <0.01 |
|  | (3 cycles) | STAI 58.40 ± 7.30 | (10) | ||||||
PAF 270.20 ± 82.61 | |||||||||
PAF 176.7 ± 61.33 (p = 0.530) | |||||||||
20 | Cirsium japonicum25 120 mg -Tablet | 1/day | 10 | Not recorded | BDI 33.60 ± 8.8 | BDI 30.40 ± 5.40 | Placebo | None reported | <0.01 |
(3 cycles) | STAI 50.90 ± 9.50 | STAI 52.00 ± 6.18 | (10) | ||||||
PAF 257.30 ± 74.81 | PAF 185.6 ± 53.65 | ||||||||
21 | Ginkgo biloba L.26 40 mg -Tablet | 3/day | 45 | Confirmed | Overall score 34.80 (p = 0.930) Severity of psychological symptoms 38.41 (p = 0.899) | Overall score 11.11 (p < 0.001) Severity of psychological symptoms 10.89 (p < 0.001) | Placebo | No severe AE reported | <0.001 |
@ LP | (45) | ||||||||
(2 cycles) |